Trends in Gastric Cancer Incidence According to the Clinicopathological Characteristics in Korea, 1999-2014

Bang Wool Eom; Kyu-Won Jung; Young-Joo Won; Hannah Yang; Young-Woo Kim

doi:10.4143/crt.2017.464

Articles

Page Path: HOME > Cancer Res Treat > Volume 50(4); 2018 > Article

Original Article Trends in Gastric Cancer Incidence According to the Clinicopathological Characteristics in Korea, 1999-2014: Bang Wool Eom, MD, PhD¹, Kyu-Won Jung, MS², Young-Joo Won, PhD^2,, Hannah Yang, BS¹, Young-Woo Kim, MD, PhD^1,3,; Cancer Research and Treatment : Official Journal of Korean Cancer Association 2018;50(4):1343-1350.
DOI: https://doi.org/10.4143/crt.2017.464
Published online: January 15, 2018

¹Center for Gastric Cancer, National Cancer Center, Goyang, Korea

²Cancer Registration and Statistics Branch, National Cancer Control Institute, Goyang, Korea

³Department of Cancer Control and Population Health, Graduate School of Cancer Science and Policy, Goyang, Korea

Correspondence: Young-Woo Kim, MD, PhD Department of Cancer Control and Population Health, Graduate School of Cancer Science and Policy, 323 Ilsan-ro, Ilsandong-gu, Goyang 10408, Korea
Tel: 82-31-920-1635 Fax: 82-31-920-0069 E-mail: gakim@ncc.re.kr

Co-correspondence: Young-Joo Won, PhD Cancer Registration and Statistics Branch, National Cancer Center, 323 Ilsan-ro, Ilsandong-gu, Goyang 10408, Korea
Tel: 82-31-920-2015 Fax: 82-31-920-2179 E-mail: astra67@ncc.re.kr

*Bang Wool Eom and Kyu-Won Jung contributed equally to this work.

• Received: September 29, 2017 • Accepted: January 14, 2018

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

9,833 Views
275 Download
52 Web of Science
52 Crossref
50 Scopus

prev next

Full Article

Download PDF

Abstract

Purpose
The aim of this study was to evaluate recent trends in gastric cancer incidence according to the age, sex, and tumor location in the Korean population.
Materials and Methods
Using data from the Korea Central Cancer Registry between 1999 and 2014, gastric cancer incidence, annual percent changes, and male-to-female incidence rate ratios (IRRs) according to tumorlocationwere determined. The distribution of disease extent according to the tumor location and its changes between 2006 and 2014 were also analyzed.
Results
Incidence of gastric cancer was stable until 2011 and decreased between 2011 and 2014. The age-standardized incidence rate of gastric cancer was 43.6 (per 100,000) in 1999 and 35.8 in 2014. The proportion of cardia/fundus cancer remained stable (5.9% to 7.1%), and that of body cancer increased (35.3% to 43.2%). The male-to-female IRR decreased in most age groups, except for those in their 60s. In the distribution of disease extent, the proportion of localized disease increased, and regional and distant disease decreased in all tumor locations (53.9% to 66.0%, 31.4% to 22.5%, and 14.8% to 11.5%, respectively; p < 0.001). For histological type, the proportion of carcinoid tumor and non-epithelial tumor increased (0.3% to 1.0%, and 0.8% to 1.4%, respectively).
Conclusion
In the 15 years from 1999 through 2014, age-standardized incidence of gastric cancer started to decrease from 2012, and the proportion of cardia/fundus cancer remained unchanged. The trend of increasing localized cancer was observed in all tumor locations.
Key words: Stomach neoplasms, Epidemiology, Incidence, Korea

Introduction

Gastric cancer is the fifth most common cancer and the third leading cause of cancer mortality worldwide [1]. Although the incidence of gastric cancer has been decreasing in developed countries, 1.3 million new cases of gastric cancer and 819,000 deaths were still reported in 2015. In the Republic of Korea, gastric cancer ranks second in cancer incidence and third in cancer mortality [2]. Approximately 30,000 new gastric cancer cases and about 9,000 deaths were reported in 2014.

Previous studies using the Korea Central Cancer Registry (KCCR), a nationwide cancer database, analyzed the incidence, mortality, survival, and prevalence of 23 cancer types since its first functional year in 1999 [2,3]. However, these studies did not evaluate incidence stratified by specific clinicopathological factors, such as tumor location, stage, and histology.

Another nationwide epidemiological study for gastric cancer, which was performed by the Korean Gastric Cancer Association (KGCA), did evaluate incidence according to clinicopathological factors, such as tumor location and pathological TNM [4]. However, only surgically treated patients were included in its survey data. Meaning, patients who received endoscopic or chemotherapeutic treatment were excluded from this study, and the KGCA statistics therefore did not depict an accurate portrayal of the overall gastric cancer status in Korea. To our knowledge, no previous studies have analyzed trends in gastric cancer incidence according to the specific characteristics using nationwide cancer data in Korea.

Domestically, reports evaluating nationwide trends in cancer incidence are necessary for the development of up-todate and evidence-based health care policies and guidelines by both clinicians and policy makers. For example, policy makers can analyze the effectiveness of Korea’s National Cancer Control Program and update their recommendations and initiatives accordingly. On a larger scale, these epidemiological reports can also advance general understating of cancer etiology in the context of treated patients. Clinicians can assess the effect of biological and environmental risk factors on cancer incidence, and focus on important factors to prevent and treat cancer.

The aim of this study was to evaluate recent trends in gastric cancer incidence according to clinicopathological factors using the KCCR. In particular, specific incidences of gastric cancer according to tumor location were determined.

Materials and Methods

1. Data sources

When the KCCR was launched in 1980 by the Ministry of Health and Welfare, Korea, this database initially collected information on cancer cases only from training hospitals and then expanded to collecting nationwide data in 1999, by integrating the hospital-based KCCR database with data from regional cancer registry programs [3]. Currently, the KCCR provides nationwide cancer incidence, survival, and prevalence statistics annually.

Gastric cancer incidence data between 1999 and 2014 were obtained from the KCCR. Anatomical tumor location was classified based on the 10th version of the International Statistical Classification of Disease and Related Health Problems (ICD-10) and divided into four categories in this study: (1) cardia (C16.0) and fundus (C16.1), (2) body (C16.2), (3) antrum (C16.3) and pylorus (C16.4), and (4) non-specific including lesser curvature (C16.5), greater curvature (C16.6), overlapping lesion (C16.8), and unspecified (C16.9) [5]. The histology of gastric cancers was classified into six groups: tubular adenocarcinoma (ICD-O-3: 8140/3, 8143/3, 8144/3, 8190/3, 8210/3, 8211/3, 8221/3, 8255/3, 8261/3-8263/3), signet ring cell carcinoma (ICD-O-3: 8145/3, 8490/3), other carcinoma, carcinoid tumor (ICD-O-3: 8013/3, 8153/3, 8240/3-8246/3, 8249/3, 9364/3, 9473/3), non-epithelial, and unclassified (ICD-O-3: 8000/3, 8001/3, 8010/3, 8142/3, 8050/3, 8052/3).

Stage at diagnosis was classified as localized (invasive cancer confined to the organ of origin), regional (spread to adjacent organs by direct extension and/or regional lymph node metastasis), distant (extension to organs other than those covered in the regional category or metastases to distant organs or distant lymph nodes), or unknown.

The KCCR records constituted the best available information on the stage of disease as it appears in the medical record within 4 months of diagnosis.

2. Statistical analysis

The age-standardized incidence rates per 100,000 people were calculated as the sum of the expected age-specific rates divided by the sum of the standard population [6]. The sum of the expected age-specific rates was obtained by multiplying the age-specific incidence rates among study population by the proportion of population in the corresponding agespecific groups among standard population. We used the Segi’s world population as the standard population, and the structure of the standard population is shown in S1 Table. Annual percent changes (APCs) for the incidence rates is calculated using a linear model, according to the following formula; (exp(β)–1)×100, where the regression coefficient (β) is the slope of the regression of the natural logarithm of the agestandardized rate (ASR) in a calendar year [7]. The 95% confidence intervals (CIs) were obtained with a standard error from the fit of the regression and the t-distribution function.

Male-to female incidence rate ratios (IRR) were calculated using the numbers of cancer patients for each tumor location and the sex-specific population structure for each year [8]. Statistical significance in difference between IRRs was determined if the 95% CIs did not overlap between IRRs.

The most recent (2014) male-to female IRRs was compared to those of 2004, because we thought that 10 years of interval is appropriate to evaluate the trend of IRRs. The Surveillance Epidemiology and End Results (SEER) stage distributions were compared between 2006 and 2014, because SEER stage data have been collected since 2005 in KCCR and the 2006 data is the oldest reliable one.

A p-value of < 0.05 indicated statistical significance. All analyses were conducted using the R-2.12.2 (http://cran.r-project.org) software and STATA ver. 11.0 (StataCorp LP, College Station, TX).

3. Ethical statement

This study was approved by the Institutional Review Board at the National Cancer Center, Korea (No. NCC2017-0012) and performed in accordance with the principles of the Declaration of Helsinki. The informed consent was waived.

Results

1. Changes of gastric cancer incidences according to the age and tumor location

Overall gastric cancer incidence and incidences by tumor location are shown in Table 1. Incidence of gastric cancer increased from 20,870 in 1999 to 31,937 in 2011, and then slightly decreased to 29,854 in 2014. The ASR was maintained, ranging from 41.2 to 44.4 per 100,000 between 1999 and 2011, but decreased to 35.8 in 2014.

The antrum/pylorus was the most common location throughout all periods. Incidence and ASR of cardia/fundus, body, and antrum/pylorus cancer slightly increased, and those of non-specific markedly decreased. When the cases classified as non-specific were excluded, the proportion of cardia/fundus cancer had little change, the body cancer increased from 35.3% in 1999 to 43.2% in 2014, and the antrum/pylorus cancer decreased from 58.0% in 1999 to 50.6% in 2014. The positive values of APCs for cardia/fundus, body, and antrum/pylorus cancer can be associated with a negative APC value for non-specific tumors (1.3, 3.7, and 1.3 in the cardia/fundus, body, and antrum/pylorus cancer respectively, and –8.5 in the non-specific tumor).

Fig. 1 demonstrates incidence rates per 100,000 according to the age groups in each location. The incidence rate was the highest in 70-79-year-old age group followed by the age groups of ≥ 80, 60-69, 50-59, 40-49, and 30-39 years.

2. Changes of male-to-female ratios according to the age and tumor location

The male-to-female IRRs according to the age groups in 2004 and 2014 are shown in Table 2. Generally, male patients occupied 2 to 3 times of female patients in most age groups. The highest male-to-female IRRs were observed in the 60s and the lowest in the 30s.

For overall gastric cancer, male-to-female IRRs significantly decreased in the 40s (1.8 in 2004 vs. 1.5 in 2014; p < 0.001). For body cancer, it significantly decreased in 30s, 40s, and 60s (p=0.003, p=0.006, and p=0.011, respectively).

3. Changes of SEER stage at diagnosis according to tumor location

Distributions of SEER stage by tumor location are shown in Table 3. In overall gastric cancer, the proportion of localized cancer increased from 53.9% in 2006 to 66.0% in 2014, and those of regional and distant cancer decreased from 31.4% to 22.5% and 14.8% to 11.5%, respectively (p < 0.001). These changes of increased localized cancer and decreased regional and distant cancer were observed in each tumor location.

4. Changes of SEER stage at diagnosis in 30s and others

The change of SEER stage was specifically evaluated in the 30s, because the National Cancer Screening Program is performed for patients above 40 years. Compared to patients older than 40 years, patients in their 30s experienced lower rates of localized cancer but higher rates of regional or distant cancer (Table 4). However, the changes between 2006 and 2014 were similar in both the 30s and 40 or more populations; the proportion of localized cancer increased from 45.3% to 55.5% between 2006 and 2014, and regional and distant cancer decreased from 33.4% to 24.3% and 21.3% to 20.2% between 2006 and 2014, respectively.

5. Changes of incidence and proportion according to histology

Table 5 demonstrates incidence and proportion according to histology. The proportion of each histological type was calculated excluding unclassified tumors. Most common histology was tubular adenocarcinoma followed by signet ring cell, other carcinoma, non-epithelial tumor, and carcinoid tumor. The proportions of carcinoid tumor and non-epithelial tumor increased from 0.3% to 1.0% and 0.8% to 1.4% between 1999 and 2014, respectively. However, the proportion of other carcinoma decreased from 3.8% to 3.1% between 1999 and 2014. The proportions of tubular adenocarcinoma and signet ring cell were stable.

Discussion

In this study, we evaluated recent trends in gastric cancer incidence according to tumor location, stage, and histology using the KCCR database. Between 1999 and 2014, the incidence of gastric cancer decreased, but the proportion of cardia/fundus cancer has remained stable so far. Localized gastric cancer increased in all tumor locations, and an increase in carcinoid and non-epithelial tumors was also observed.

Gastric cancer ranks as the second-most common cancer following thyroid cancer in Korea, but only a few longitudinal studies evaluating its incidence have been performed thus far [2,9-11]. Previous nationwide longitudinal studies that reported these results, however, did not stratify data by specific clinicopathological factors or encompass patients treated by non-surgical modalities. A study by Song et al. [10] revealed age- and sex-specific gastric cancer incidence and APCs from 1999 to 2010 using the KCCR data, but no other clinical factors except age and sex in the study was studies.

Disparity in the tumor location of gastric tumors between the East and West is well known [12-15]. While the majority of gastric cancers in the East are located in the distal part of the stomach (antrum/pylorus), proximal gastric cancers (cardia/fundus) are more common in Western countries. However, recent studies using large surgical cohorts showed increased incidence of proximal gastric cancer in Japan and Korea [9,16]. The proportion of cardia cancer increased from 2.3% (1962-1965) to 10.0% (2001-2005) in the Japanese cohort and from 11.2% (1995) to 16.0% (2014) in the Korean cohort. Considering the transition towards a westernized life-style and increased rates of obesity in East Asia, we hypothesized that a gradual increase of proximal gastric cancers would be observed in this study. However, no significant change in the proportion of proximal gastric cancer was found; the proportion consistently ranged between 6% and 7% in all gastric cancer cases in Korea.

Proximal location is known to be a negative prognostic factor because of its association with advanced stages and high metastasis rates [17-19]. The change in SEER stage according to the tumor location was therefore evaluated, and the proportion of patients with localized cancer was found to be smaller in cardia/fundus cancers than in antrum/pylorus cancers. However, overall incidence of localized tumors in both cardia/fundus and antrum/pylorus locations increased. Even the proportion of localized tumors in young patients aged 30-39, who are not covered by the National Cancer Screening Program, increased from 45% to 56%. This trend of increased incidence in localized cancer was found in all tumor locations and age groups.

This study has several limitations. First, as the proportion of non-specific tumor location decreased, other specific tumor locations increased. These changes can be explained by improved accuracy in topology coding. The National Endoscopy Quality Improvement Program which was initiated in 2009 probably affected the topical accuracy, and it was recommended that information about the location, shape, and size of lesion are reported in endoscopic finding [20,21]. Therefore, positive APC values of each specific tumor location (cardia/fundus, body, and antrum/pylorus) are not actual increases. Instead, the relative proportion of each tumor location can suggest actual changes of gastric cancer incidence according to the tumor location. Second, approximately 15% (4,458/29,854 in 2014) of tumor location was unspecified. Even though the proportion of non-specific tumors gradually decreased throughout the timeframe of this study, these non-specific tumors could potentially skew the available data. Improvements in the KCCR data supplementation policies and increased effort by physicians can decrease the proportion of non-specific entities in the future.

These findings describing changes in gastric cancer incidence and trends when stratified by specific clinicopathological factors warrants further studies to investigate the cause of these noted changes. In turn, this information can be valuable when revising current guidelines to implement more effective prevention and surveillance programs for gastric cancer.

In the 15 years from 1999 through 2014, age-standardized incidence of gastric cancer started to decrease from 2012, and the proportion of cardia/fundus cancer remained unchanged. The trend of increasing localized cancer was observed in all tumor locations.

Electronic Supplementary Material

Supplementary materials are available at Cancer Research and Treatment website (http://www.e-crt.org).

crt-2017-464-suppl1.pdf

NOTES

Conflict of interest relevant to this article was not reported.

Acknowledgements

This work was supported by a grant of the National Cancer Center (No. NCC-1710120-1 and NCC-1610200).

Fig. 1.

Incidence rates (per 100,000) of gastric cancer by age groups.

Table 1.

Age-standardized gastric cancer incidence rates per 100,000 and APCs by tumor location

Year	Overall		Cardia/Fundus		Body		Antrum/Pylorus		Non-specific
Year	No.	ASR^a)	No. (%)^b)	ASR^a)	No. (%)^b)	ASR^a)	No. (%)^b)	ASR^a)	No.	ASR^b)
1999	20,870	43.6	775 (6.8)	1.6	4,030 (35.3)	8.3	6,623 (58.0)	14.0	9,442	19.7
2000	20,972	42.3	813 (7.1)	1.7	4,067 (35.5)	8.1	6,591 (57.5)	13.4	9,501	19.1
2001	22,541	44.0	878 (6.6)	1.7	4,929 (37.3)	9.5	7,405 (56.0)	14.6	9,329	18.1
2002	23,220	43.6	999 (7.0)	1.9	5,223 (36.4)	9.7	8,123 (56.6)	15.4	8,875	16.6
2003	23,927	43.3	1,016 (6.8)	1.8	5,548 (37.0)	10.0	8,434 (56.2)	15.4	8,929	16.1
2004	23,636	41.2	1,013 (6.7)	1.8	5,737 (38.1)	10.0	8,304 (55.2)	14.6	8,582	14.9
2005	26,367	44.4	1,114 (6.3)	1.9	6,816 (38.4)	11.5	9,806 (55.3)	16.6	8,631	14.4
2006	26,434	42.9	1,208 (6.4)	2.0	7,173 (38.2)	11.6	10,386 (55.3)	17.0	7,667	12.3
2007	26,820	41.8	1,251 (6.3)	2.0	7,739 (39.1)	12.1	10,799 (54.6)	16.9	7,031	10.8
2008	28,394	42.6	1,326 (6.1)	2.0	8,664 (39.8)	13.1	11,758 (54.1)	17.8	6,646	9.8
2009	30,019	43.4	1,382 (5.9)	2.0	9,345 (39.8)	13.7	12,754 (54.3)	18.5	6,538	9.3
2010	30,680	42.6	1,495 (6.2)	2.1	9,534 (39.6)	13.4	13,056 (54.2)	18.2	6,595	9.0
2011	31,937	42.9	1,668 (6.3)	2.2	10,938 (41.5)	14.9	13,759 (52.2)	18.5	5,572	7.3
2012	31,067	40.2	1,662 (6.4)	2.1	10,993 (42.1)	14.5	13,442 (51.5)	17.3	4,970	6.2
2013	30,328	37.6	1,582 (6.2)	2.0	10,672 (42.0)	13.6	13,181 (51.8)	16.2	4,893	5.8
2014	29,854	35.8	1,566 (6.2)	1.9	10,981 (43.2)	13.6	12,849 (50.6)	15.2	4,458	5.1
APC (95% CI)	–0.9 (–1.4 to –0.3)		1.3 (0.6 to 2.1)		3.7 (2.9 to 4.6)		1.3 (0.3 to 2.2)		–8.5 (–9.3 to –7.7)
p-value	< 0.001		< 0.001		< 0.001		< 0.001		< 0.001

APC, annual percent changes; ASR, age-standardized rate; CI, confidence interval.

^a) The Segi’s world population was used as standard population,

^b) Proportions of each tumor location excluding non-specific.

Table 2.

Male to female gastric cancer incidence rate ratio by tumor location

Age (yr)	Overall			Cardia/Fundus			Body			Antrum/Pylorus
Age (yr)	2004	2014	p-value	2004	2014	p-value	2004	2014	p-value	2004	2014	p-value
30-39	0.9 (0.8-1.0)	0.8 (0.7-0.9)	0.118	1.4 (0.8-2.4)	1.5 (0.8-2.8)	0.862	0.8 (0.7-1.0)	0.5 (0.5-0.6)	0.003	1.3 (1.1-1.6)	1.4 (1.1-1.9)	0.658
40-49	1.8 (1.6-1.9)	1.5 (1.4-1.6)	< 0.001	1.7 (1.2-2.4)	2.1 (1.5-3.0)	0.367	1.3 (1.1-1.5)	1.0 (0.9-1.1)	0.006	2.6 (2.3-3.0)	2.2 (2.0-2.5)	0.087
50-59	2.8 (2.6-3.0)	2.7 (2.6-2.9)	0.413	3.2 (2.3-4.3)	2.9 (2.3-3.8)	0.739	2.2 (1.9-2.4)	2.1 (1.9-2.2)	0.545	3.3 (2.9-3.6)	3.5 (3.2-3.8)	0.326
60-69	3.1 (2.9-3.2)	3.2 (3.1-3.4)	0.225	4.5 (3.6-5.8)	4.0 (4.0-6.2)	0.638	3.4 (3.1-3.8)	2.9 (2.7-3.1)	0.011	2.8 (2.6-3.0)	3.2 (3.0-3.5)	0.017
70-79	2.7 (2.5-2.8)	2.7 (2.6-2.8)	0.986	3.8 (2.9-5.0)	3.9 (3.2-4.7)	0.878	3.0 (2.7-3.4)	3.0 (2.8-3.3)	0.913	2.5 (2.3-2.8)	2.3 (2.2-2.5)	0.206
≥ 80	2.6 (2.4-2.9)	2.5 (2.3-2.7)	0.454	3.7 (2.3-6.1)	3.5 (2.6-4.6)	0.830	3.7 (2.9-4.8)	2.8 (2.5-3.3)	0.097	2.8 (2.3-3.3)	2.4 (2.2-2.7)	0.230

Table 3.

SEER stage distribution according to tumor location between 2006 and 2014

Tumor location	SEER	2006	2014	p-value
Overall	Localized	11,712 (53.9)	18,572 (66.0)	< 0.001
	Regional	6,819 (31.4)	6,335 (22.5)
	Distant	3,213 (14.8)	3,242 (11.5)
	Unknown	4,690	1,705
Cardia/Fundus	Localized	466 (44.4)	799 (54.2)	< 0.001
	Regional	392 (37.3)	453 (30.8)
	Distant	192 (18.3)	221 (15.0)
	Unknown	158	93
Body	Localized	3,497 (55.6)	6,999 (66.1)	< 0.001
	Regional	1,952 (31.0)	2,447 (23.1)
	Distant	841 (13.4)	1,136 (10.7)
	Unknown	883	399
Antrum/Pylorus	Localized	5,308 (59.3)	8,728 (70.8)	< 0.001
	Regional	2,671 (28.8)	2,589 (21.0)
	Distant	972 (10.9)	1,010 (8.2)
	Unknown	1,435	522

Values are presented as number (%). SEER, Surveillance Epidemiology and End Results.

Table 4.

SEER stage distribution in 30s and 40s or more between 2006 and 2014

Age group (yr)	SEER	2006	2014	p-value
30-39	Localized	508 (45.3)	453 (55.5)	< 0.001
	Regional	375 (33.4)	198 (24.3)
	Distant	239 (21.3)	165 (20.2)
	Unknown	128	21
≥ 40	Localized	11,130 (54.4)	18,076 (66.4)	< 0.001
	Regional	6,396 (31.3)	6,118 (22.5)
	Distant	2,931 (14.3)	3,048 (11.2)
	Unknown	4,533	1,680

SEER, Surveillance Epidemiology and End Results.

Table 5.

Incidences according to the histological classification

Year	Tubular adenocarcinoma	Signet ring cell	Other carcinoma	Carcinoid tumor	Non-epithelial tumor	Unclassified
1999	13,153 (75.9)^a)	3,348 (19.3)	653 (3.8)	50 (0.3)	133 (0.8)	3,533
2000	13,553 (75.8)	3,443 (19.3)	672 (3.8)	49 (0.3)	156 (0.9)	3,099
2001	14,964 (75.6)	3,918 (19.8)	660 (3.3)	45 (0.2)	199 (1.0)	2,755
2002	15,566 (75.4)	4,107 (19.9)	697 (3.4)	71 (0.3)	203 (1.0)	2,576
2003	16,334 (75.4)	4,235 (19.6)	778 (3.6)	79 (0.4)	227 (1.0)	2,274
2004	16,010 (74.2)	4,521 (20.9)	710 (3.3)	110 (0.5)	236 (1.1)	2,049
2005	18,357 (75.5)	4,755 (19.6)	832 (3.4)	128 (0.5)	232 (1.0)	2,063
2006	18,894 (76.1)	4,756 (19.2)	782 (3.2)	124 (0.5)	258 (1.0)	1,620
2007	18,973 (75.3)	5,006 (19.9)	828 (3.3)	133 (0.5)	260 (1.0)	1,620
2008	20,506 (75.6)	5,353 (19.7)	856 (3.2)	141 (0.5)	252 (0.9)	1,286
2009	21,877 (75.8)	5,576 (19.3)	951 (3.3)	174 (0.6)	282 (1.0)	1,159
2010	22,526 (76.4)	5,577 (18.9)	867 (2.9)	217 (0.7)	310 (1.1)	1,183
2011	23,488 (76.2)	5,870 (19.1)	865 (2.8)	255 (0.8)	328 (1.1)	1,131
2012	22,916 (76.2)	5,631 (18.7)	895 (3.0)	278 (0.9)	341 (1.1)	1,006
2013	21,982 (74.9)	5,849 (19.9)	918 (3.1)	260 (0.9)	356 (1.2)	963
2014	21,430 (74.0)	5,947 (20.5)	902 (3.1)	277 (1.0)	395 (1.4)	903
APC (95% CI)	3.8 (3.0-4.6)	3.8 (3.2-4.4)	2.4 (1.8-3.0)	13.0 (11.1-14.9)	5.9 (5.1-6.7)
p-value	< 0.001	< 0.001	< 0.001	< 0.001	< 0.001

Values are presented as number (%). APC, annual percent changes; CI, confidence interval.

^a) Proportion of each histological type among whole types excluding unclassified.

REFERENCES

1. Global Burden of Disease Cancer Collaboration, Fitzmaurice C, Allen C, Barber RM, Barregard L, Bhutta ZA, et al. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted lifeyears for 32 cancer groups, 1990 to 2015: a systematic analysis for the global burden of disease study. JAMA Oncol. 2017;3:524–48. Article PubMed PMC
2. Jung KW, Won YJ, Oh CM, Kong HJ, Lee DH, Lee KH, et al. Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2014. Cancer Res Treat. 2017;49:292–305. Article PubMed PMC PDF
3. Shin HR, Won YJ, Jung KW, Kong HJ, Yim SH, Lee JK, et al. Nationwide cancer incidence in Korea, 1999~2001; first result using the national cancer incidence database. Cancer Res Treat. 2005;37:325–31. Article PubMed PMC PDF
4. Korean Gastric Cancer Association. Nationwide gastric cancer report in Korea. J Korean Gastric Cancer Assoc. 2002;2:105–14. Article PDF
5. World Health Organization. International statistical classification of diseases and related health problems. 10th rev. ed. Geneva: World Health Organization; 2016.
6. Howlader N, Noone AM, Krapcho M, Miller D, Bishop K, Kosary CL, et al. SEER cancer statistics review, 1975-2014. Bethesda, MD: National Cancer Institute; 2017.
7. Altekruse SF, Kosary CL, Krapcho M, Neyman N, Aminou R, Waldron W, et al. SEER cancer statistics review, 1975-2007. Bethesda, MD: National Cancer Institute; 2010.
8. Boyle P, Parkin DM. Statistical methods for registries. In: Jensen OM, Parkin DM, MacLennan R, Muir CS, Skeet RG, editors. Cancer registration: principles and methods. Lyon: IARC Press; 1991. p. 126–58.
9. Information Committee of Korean Gastric Cancer Association. Korean Gastric Cancer Association nationwide survey on gastric cancer in 2014. J Gastric Cancer. 2016;16:131–40. Article PubMed PMC PDF
10. Song M, Kang D, Yang JJ, Choi JY, Sung H, Lee Y, et al. Age and sex interactions in gastric cancer incidence and mortality trends in Korea. Gastric Cancer. 2015;18:580–9. Article PubMed
11. Shin A, Kim J, Park S. Gastric cancer epidemiology in Korea. J Gastric Cancer. 2011;11:135–40. Article PubMed PMC
12. Schwarz RE, Zagala-Nevarez K. Ethnic survival differences after gastrectomy for gastric cancer are better explained by factors specific for disease location and individual patient comorbidity. Eur J Surg Oncol. 2002;28:214–9. Article PubMed
13. Yao JC, Schnirer II, Reddy S, Chiang S, Najam A, Yu C, et al. Effects of sex and racial/ethnic group on the pattern of gastric cancer localization. Gastric Cancer. 2002;5:208–12. Article PubMed
14. Strong VE, Song KY, Park CH, Jacks LM, Gonen M, Shah M, et al. Comparison of gastric cancer survival following R0 resection in the United States and Korea using an internationally validated nomogram. Ann Surg. 2010;251:640–6. Article PubMed
15. Ferro A, Peleteiro B, Malvezzi M, Bosetti C, Bertuccio P, Levi F, et al. Worldwide trends in gastric cancer mortality (1980-2011), with predictions to 2015, and incidence by subtype. Eur J Cancer. 2014;50:1330–44. Article PubMed
16. Kusano C, Gotoda T, Khor CJ, Katai H, Kato H, Taniguchi H, et al. Changing trends in the proportion of adenocarcinoma of the esophagogastric junction in a large tertiary referral center in Japan. J Gastroenterol Hepatol. 2008;23:1662–5. Article PubMed
17. Ohno S, Tomisaki S, Oiwa H, Sakaguchi Y, Ichiyoshi Y, Maehara Y, et al. Clinicopathologic characteristics and outcome of adenocarcinoma of the human gastric cardia in comparison with carcinoma of other regions of the stomach. J Am Coll Surg. 1995;180:577–82. PubMed
18. Pacelli F, Papa V, Caprino P, Sgadari A, Bossola M, Doglietto GB. Proximal compared with distal gastric cancer: multivariate analysis of prognostic factors. Am Surg. 2001;67:697–703. Article PubMed PDF
19. Talamonti MS, Kim SP, Yao KA, Wayne JD, Feinglass J, Bennett CL, et al. Surgical outcomes of patients with gastric carcinoma: the importance of primary tumor location and microvessel invasion. Surgery. 2003;134:720–7. Article PubMed
20. Cha JM. Quality improvement of gastrointestinal endoscopy in Korea: past, present, and future. Korean J Gastroenterol. 2014;64:320–32. Article PubMed
21. Cho YK. How to improve the quality of screening endoscopy in Korea: national endoscopy quality improvement program. Clin Endosc. 2016;49:312–7. Article PubMed PMC PDF

Figure & Data

REFERENCES

Citations

Citations to this article as recorded by

Lymph Node Yield and Lymph Node Ratio for Prognosis of Long-Term Survival in Gastric Carcinoma
Olof Jannasch, Martin Schwanz, Ronny Otto, Michal Mik, Hans Lippert, Pawel Mroczkowski
Cancers.2025; 17(3): 414. CrossRef
The relationship between the eradication of Helicobacter pylori and the occurrence of stomach cancer: an updated meta-analysis and systemic review
Zhouhan Wu, Yi Tang, Meiwen Tang, Zhoutong Wu, Yonghui Xu
BMC Gastroenterology.2025;[Epub] CrossRef
Impact of Smoking and Alcohol Consumption on Early-Onset Gastric Cancer Development in Young Koreans: A Population-Based Study
Seung Joo Kang, Cheol Min Shin, Kyungdo Han, Jin Hyung Jung, Eun Hyo Jin, Joo Hyun Lim, Yoon Jin Choi, Hyuk Yoon, Young Soo Park, Nayoung Kim, Dong Ho Lee
Journal of Gastric Cancer.2024; 24(2): 145. CrossRef
Population‐based evaluation of disparities in stomach cancer by nativity among Asian and Hispanic populations in California, 2011–2015
Eunjung Lee, Kai‐Ya Tsai, Juanjuan Zhang, Amie E. Hwang, Dennis Deapen, Jennifer J. Koh, Eric S. Kawaguchi, James Buxbaum, Sang Hoon Ahn, Lihua Liu
Cancer.2024; 130(7): 1092. CrossRef
Autoimmune conditions and gastric cancer risk in a population-based study in the United Kingdom
John D. Murphy, Shahinaz M. Gadalla, Lesley A. Anderson, Charles S. Rabkin, Chris R. Cardwell, Minkyo Song, M. Constanza Camargo
British Journal of Cancer.2024; 131(1): 138. CrossRef
Long-Term Outcome of Proximal Gastrectomy for Upper-Third Advanced Gastric and Siewert Type II Esophagogastric Junction Cancer Compared With Total Gastrectomy: A Propensity Score-Matched Analysis
Seungho Lee, Yoon Soo Chae, Won-Gun Yun, Jane Chungyoon Kim, Jae Kyun Park, Min Gyu Kim, Jeesun Kim, Yo-Seok Cho, Seong-Ho Kong, Do Joong Park, Hyuk-Joon Lee, Han-Kwang Yang
Annals of Surgical Oncology.2024; 31(5): 3024. CrossRef
Risk prediction model for gastric cancer within 5 years in healthy Korean adults
Hyungseok Oh, Sunwoo Cho, Jung Ah Lee, Seungho Ryu, Yoosoo Chang
Gastric Cancer.2024; 27(4): 675. CrossRef
Gastric neuroendocrine neoplasms
Giuseppe Lamberti, Francesco Panzuto, Marianne Pavel, Dermot O’Toole, Valentina Ambrosini, Massimo Falconi, Rocio Garcia-Carbonero, Rachel P. Riechelmann, Guido Rindi, Davide Campana
Nature Reviews Disease Primers.2024;[Epub] CrossRef
Comparing global trends in gastric cancer and the need for national screening programs: An in-depth literature review
Aditya Mavinkurve, Mahul Patel, Amanda Shabana, Teesta Das
Open Health.2024;[Epub] CrossRef
Increasing disparities in the proportions of active treatment and 5-year overall survival over time by age groups among older patients with gastric cancer in Korea
Hyun-Soo Zhang, Dong-Woo Choi, Han Sang Kim, Hye Jung Kang, Hoyol Jhang, Wonjeong Jeong, Chung Mo Nam, Sohee Park
Frontiers in Public Health.2023;[Epub] CrossRef
Risk of Gastric Cancer among Patients with Newly Diagnosed Ulcerative Colitis: A Nationwide Population-Based Study
Hee Man Kim, Jihoon Kim, Hyunil Kim, Soon Chang Park, Jung Kuk Lee, Dae Ryong Kang, Su Young Kim, Hyun-Soo Kim
Journal of Clinical Medicine.2023; 12(8): 2843. CrossRef
Efficacy of Lymph Node Location-Number Hybrid Staging System on the Prognosis of Gastric Cancer Patients
Junpeng Wu, Hao Wang, Xin Yin, Xibo Wang, Yufei Wang, Zhanfei Lu, Jiaqi Zhang, Yao Zhang, Yingwei Xue
Cancers.2023; 15(9): 2659. CrossRef
Genomic differentiation within East Asian Helicobacter pylori
Yuanhai You, Kaisa Thorell, Lihua He, Koji Yahara, Yoshio Yamaoka, Jeong-Heon Cha, Kazunari Murakami, Yukako Katsura, Ichizo Kobayashi, Daniel Falush, Jianzhong Zhang
Microbial Genomics .2022;[Epub] CrossRef
Development and external validation of a nomogram for individualized adjuvant imatinib duration for high‐risk gastrointestinal stromal tumors: A multicenter retrospective cohort study
Ruolin Liu, Yingxin Wu, Jin Gong, Rui Zhao, Li Li, Qianyi Wan, Nan Lian, Xiaoding Shen, Lin Xia, Yuhou Shen, Haitao Xiao, Xiaoting Wu, Yi Chen, Ying Cen, Xuewen Xu
Cancer Medicine.2022; 11(16): 3093. CrossRef
20-Year Trends in Detection Rates of Cardia Cancer via Endoscopic Surveillance in Tianjin, China: A Hospital-Based Study
Rui Wang, Xiaowei Wu, Yan Song, Rui Lin, Zhongqing Zheng, Kui Jiang, Wentian Liu, Min Tang
Computational and Mathematical Methods in Medicine.2022; 2022: 1. CrossRef
Declining trends of prevalence ofHelicobacter pyloriinfection and incidence of gastric cancer in Taiwan: An updated cross‐sectional survey and meta‐analysis
Mei‐Jyh Chen, Ming‐Jong Bair, Po‐Yueh Chen, Ji‐Yuh Lee, Tsung‐Hua Yang, Yu‐Jen Fang, Chieh‐Chang Chen, An‐Ti Chang, Wang‐De Hsiao, Jian‐Jyun Yu, Chia‐Chi Kuo, Min‐Chin Chiu, Kun‐Pei Lin, Min‐Horn Tsai, Yao‐Chun Hsu, Chu‐Kuang Chou, Chi‐Yi Chen, Jaw‐Town L
Helicobacter.2022;[Epub] CrossRef
Epidemiology of Gastric Cancer in Korea: Trends in Incidence and Survival Based on Korea Central Cancer Registry Data (1999–2019)
Sin Hye Park, Mee Joo Kang, E Hwa Yun, Kyu-Won Jung
Journal of Gastric Cancer.2022; 22(3): 160. CrossRef
Decreasing Incidence of Gastric Cancer with Increasing Time after Helicobacter pylori Treatment: A Nationwide Population-Based Cohort Study
Taewan Kim, Seung In Seo, Kyung Joo Lee, Chan Hyuk Park, Tae Jun Kim, Jinseob Kim, Woon Geon Shin
Antibiotics.2022; 11(8): 1052. CrossRef
Clinicopathological difference between gastric cancer in the lesser curvature and gastric cancer in the greater curvature
Guo-Cai Li, Hong-Wei Zhang, Hong-Gang Tian, Yun Zhao, Qin-Xian Huang, Ze-Yu Xu, Xiao-Hui Xi, Kai Zhang
Medicine.2022; 101(33): e29984. CrossRef
Impact of Cardiovascular Diseases on Mortality in Gastric Cancer Patients with Preexisting Chronic Disease
Kyu-Tae Han, Dong Wook Kim, Woorim Kim
Yonsei Medical Journal.2022; 63(11): 1043. CrossRef
Long‑term outcome of the endoscopic submucosal dissection of early gastric cancer: A comparison between patients with and without liver cirrhosis
Seung Kim, Moon Joo, Ah-Young Yoo, Seong Kim, Won Kim, Beom Lee, Jong Park, Hoon Chun, Sang Lee
Oncology Letters.2022;[Epub] CrossRef
International cost-effectiveness analysis evaluating endoscopic screening for gastric cancer for populations with low and high risk
Benjamin Ascherman, Aaron Oh, Chin Hur
Gastric Cancer.2021; 24(4): 878. CrossRef
Impact of Palliative Gastrectomy in Patients with Incurable Gastric Cancer
Ji Yeon Park, Byunghyuk Yu, Ki Bum Park, Oh Kyoung Kwon, Seung Soo Lee, Ho Young Chung
Medicina.2021; 57(3): 198. CrossRef
Clinical practice guideline for endoscopic resection of early gastrointestinal cancer
Chan Hyuk Park, Dong-Hoon Yang, Jong Wook Kim, Jie-Hyun Kim, Ji Hyun Kim, Yang Won Min, Si Hyung Lee, Jung Ho Bae, Hyunsoo Chung, Kee Don Choi, Jun Chul Park, Hyuk Lee, Min-Seob Kwak, Bun Kim, Hyun Jung Lee, Hye Seung Lee, Miyoung Choi, Dong-Ah Park, Jong
Intestinal Research.2021; 19(2): 127. CrossRef
Oncologic Feasibility of Proximal Gastrectomy in Upper Third Advanced Gastric and Esophagogastric Junctional Cancer
Won-Gun Yun, Myung-Hoon Lim, Sarah Kim, Sa-Hong Kim, Ji-Hyeon Park, Seong-Ho Kong, Do Joong Park, Hyuk-Joon Lee, Han-Kwang Yang
Journal of Gastric Cancer.2021; 21(2): 169. CrossRef
Is Splenic Hilar Lymph Node Dissection Without Splenectomy Essential for Proximal Advanced Gastric Cancer?
Yoon Jung Oh, Deok Hee Kim, Bang Wool Eom, Hong Man Yoon, Young-Woo Kim, Keun Won Ryu
Annals of Surgical Oncology.2021; 28(13): 8952. CrossRef
Preferences of first-degree relatives of gastric cancer patients for gastric cancer screening: a discrete choice experiment
Hui-qin Li, Hui Xue, Hua Yuan, Guang-ying Wan, Xiu-ying Zhang
BMC Cancer.2021;[Epub] CrossRef
Restoration for the foregut surgery: bridging gaps between foregut surgery practice and academia
Ye-lim Shin, Shin-Hoo Park, Yeongkeun Kwon, Chang Min Lee, Sungsoo Park
Journal of Minimally Invasive Surgery.2021; 24(4): 175. CrossRef
Prevalence of Regional Lymph Node Metastasis of Mucosal Gastric Signet Ring Cell Carcinoma: Analysis of the Collaborative Stage Data Survey of the Korean Central Cancer Registry
Seok-Hoo Jeong, Jin Woo Kim, Hee Man Kim
Digestive Surgery.2021; 38(5-6): 330. CrossRef
Determining the current indications for endoscopic submucosal dissection in patients with Lauren mixed‐type early gastric cancer
Jinju Choi, Hyunsoo Chung, Jung Kim, Jue Lie Kim, Sang Gyun Kim, Hyun Chae Jung
Journal of Gastroenterology and Hepatology.2020; 35(4): 586. CrossRef
Effect of histologic differences between biopsy and final resection on treatment outcomes in early gastric cancer
Yonsoo Kim, Hong Jin Yoon, Jie-Hyun Kim, Jaeyoung Chun, Young Hoon Youn, Hyojin Park, In Gyu Kwon, Seung Ho Choi, Sung Hoon Noh
Surgical Endoscopy.2020; 34(11): 5046. CrossRef
Nationwide prevalence of potential drug-drug interactions associated with non-anticancer agents in patients on oral anticancer agents in South Korea
Yun-Kyoung Song, Jung Mi Oh
Supportive Care in Cancer.2020; 28(8): 3711. CrossRef
Long-term outcomes of patients with gastric adenoma in Korea
Tae Young Park, Su Jin Jeong, Tae Hyung Kim, Jin Lee, Jongha Park, Tae Oh Kim, Yong Eun Park
Medicine.2020; 99(12): e19553. CrossRef
Clinical Practice Guideline for Endoscopic Resection of Early Gastrointestinal Cancer
Chan Hyuk Park, Dong-Hoon Yang, Jong Wook Kim, Jie-Hyun Kim, Ji Hyun Kim, Yang Won Min, Si Hyung Lee, Jung Ho Bae, Hyunsoo Chung, Kee Don Choi, Jun Chul Park, Hyuk Lee, Min-Seob Kwak, Bun Kim, Hyun Jung Lee, Hye Seung Lee, Miyoung Choi, Dong-Ah Park, Jong
Clinical Endoscopy.2020; 53(2): 142. CrossRef
Current status and trend in training for endoscopic submucosal dissection: A nationwide survey in Korea
Jae Gon Lee, Chan Hyuk Park, Hyunsoo Chung, Jun Chul Park, Do Hoon Kim, Bo-In Lee, Jeong-Sik Byeon, Hwoon-Yong Jung, Richard Bruce Mink
PLOS ONE.2020; 15(5): e0232691. CrossRef
The expression of epidermal growth factor receptor 1 and human epidermal growth factor receptor 2 based on tumor location affect survival in gastric cancer
Guo-Cai Li, Xu-Chun Jia, Qing-Chuan Zhao, Hong-Wei Zhang, Peng Yang, Long-Long Xu, Fang-Ning Pang, Jian-Bing Sun
Medicine.2020; 99(21): e20460. CrossRef
Clinical Practice Guideline for Endoscopic Resection of Early Gastrointestinal Cancer
Chan Hyuk Park, Dong-Hoon Yang, Jong Wook Kim, Jie-Hyun Kim, Ji Hyun Kim, Yang Won Min, Si Hyung Lee, Jung Ho Bae, Hyunsoo Chung, Kee Don Choi, Jun Chul Park, Hyuk Lee, Min-Seob Kwak, Bun Kim, Hyun Jung Lee, Hye Seung Lee, Miyoung Choi, Dong-Ah Park, Jong
The Korean Journal of Gastroenterology.2020; 75(5): 264. CrossRef
Effects of p-coumaric acid on microRNA expression profiles in SNU-16 human gastric cancer cells
Mi Gyeong Jang, Hee Chul Ko, Se-Jae Kim
Genes & Genomics.2020; 42(7): 817. CrossRef
Clinical Practice Guideline for Endoscopic Resection of Early Gastrointestinal Cancer
Chan Hyuk Park, Dong-Hoon Yang, Jong Wook Kim, Jie-Hyun Kim, Ji Hyun Kim, Yang Won Min, Si Hyung Lee, Jung Ho Bae, Hyunsoo Chung, Kee Don Choi, Jun Chul Park, Hyuk Lee, Min-Seob Kwak, Bun Kim, Hyun Jung Lee, Hye Seung Lee, Miyoung Choi, Dong-Ah Park, Jong
The Korean Journal of Helicobacter and Upper Gastrointestinal Research.2020; 20(2): 117. CrossRef
Vitamin D Status and Gastric Cancer: A Cross-Sectional Study in Koreans
Jung Hyun Kwak, Jean Kyung Paik
Nutrients.2020; 12(7): 2004. CrossRef
The loss of nuclear expression of single-stranded DNA binding protein 2 of gastric adenocarcinoma and its prognostic role: Analysis of molecular subtype
Seongsik Bang, Hyunsung Kim, Kiseok Jang, Seung Sam Paik, Su-Jin Shin, Valli De Re
PLOS ONE.2020; 15(8): e0236896. CrossRef
Changing trends of clinicopathologic features and survival duration after surgery for gastric cancer in Northeast China
Zhao Zhai, Zi-Yu Zhu, Xi-Liang Cong, Bang-Ling Han, Jia-Liang Gao, Xin Yin, Yu Zhang, Sheng-Han Lou, Tian-Yi Fang, Yi-Min Wang, Chun-Feng Li, Xue-Feng Yu, Yan Ma, Ying-Wei Xue
World Journal of Gastrointestinal Oncology.2020; 12(10): 1119. CrossRef
Endoscopic History and Provider Characteristics Influence Gastric Cancer Survival in Asian Americans
Christie Y. Jeon, Yu-Chen Lin, Samuel J. Klempner, Bechien U. Wu, Sungjin Kim, Kevin M. Waters, Robert W. Haile
Cancer Prevention Research.2020; 13(9): 773. CrossRef
Endoscopic Resection of Undifferentiated-type Early Gastric Cancer
Ayoung Lee, Hyunsoo Chung
Journal of Gastric Cancer.2020; 20(4): 345. CrossRef
Cycloastragenol can negate constitutive STAT3 activation and promote paclitaxel-induced apoptosis in human gastric cancer cells
Sun Tae Hwang, Chulwon Kim, Jong Hyun Lee, Arunachalam Chinnathambi, Sulaiman Ali Alharbi, Omar H.M. Shair, Gautam Sethi, Kwang Seok Ahn
Phytomedicine.2019; 59: 152907. CrossRef
Prospective Multicenter Feasibility Study of Laparoscopic Sentinel Basin Dissection after Endoscopic Submucosal Dissection for Early Gastric Cancer: SENORITA 2 Trial Protocol
Bang Wool Eom, Hong Man Yoon, Jae Seok Min, In Cho, Ji-Ho Park, Mi Ran Jung, Hoon Hur, Young-Woo Kim, Young Kyu Park, Byung-Ho Nam, Keun Won Ryu
Journal of Gastric Cancer.2019; 19(2): 157. CrossRef
Changes in the Clinical and Pathological Characteristics of Gastric Cancer during the Last 16 Years: A Study of a Single Institution in Korea
Jung Won Lee, Nayoung Kim, Yong Jae Kwon, Hye Seung Lee
The Korean Journal of Helicobacter and Upper Gastrointestinal Research.2019; 19(2): 120. CrossRef
TRP channels in gastric cancer: New hopes and clinical perspectives
Andra M. Sterea, Emmanuel E. Egom, Yassine El Hiani
Cell Calcium.2019; 82: 102053. CrossRef
Autoimmune Diseases and Gastric Cancer Risk: A Systematic Review and Meta-Analysis
Minkyo Song, Gonzalo Latorre, Danisa Ivanovic-Zuvic, M. Constanza Camargo, Charles S. Rabkin
Cancer Research and Treatment.2019; 51(3): 841. CrossRef
Prognostic Value of Metabolic Information in Advanced Gastric Cancer Using Preoperative 18F-FDG PET/CT
Hye Ryeong Kwon, Kisoo Pahk, Sungsoo Park, Hyun Woo Kwon, Sungeun Kim
Nuclear Medicine and Molecular Imaging.2019; 53(6): 386. CrossRef
Development and Validation of an Easy-to-Implement, Practical Algorithm for the Identification of Molecular Subtypes of Gastric Cancer: Prognostic and Therapeutic Implications
Jiwon Koh, Keun-Wook Lee, Soo Kyung Nam, An Na Seo, Ji-Won Kim, Jin Won Kim, Do Joong Park, Hyung-Ho Kim, Woo Ho Kim, Hye Seung Lee
The Oncologist.2019; 24(12): e1321. CrossRef
Gastric Cancer: an Evolving Disease
Minkyo Song, Charles S. Rabkin, M. Constanza Camargo
Current Treatment Options in Gastroenterology.2018; 16(4): 561. CrossRef

PubReader
ePub Link

Cite

CITE: export Copy Download Format; Close

Download Citation

Download a citation file in RIS format that can be imported by all major citation management software, including EndNote, ProCite, RefWorks, and Reference Manager.

Format:

RIS — For EndNote, ProCite, RefWorks, and most other reference management software
BibTeX — For JabRef, BibDesk, and other BibTeX-specific software

Include:

Citation for the content below
Citation and abstract for the content below

Trends in Gastric Cancer Incidence According to the Clinicopathological Characteristics in Korea, 1999-2014

Cancer Res Treat. 2018;50(4):1343-1350. Published online January 15, 2018

DOI: https://doi.org/10.4143/crt.2017.464

XML Download

Abstract
Introduction
Materials and Methods
Results
Discussion
Electronic Supplementary Material
NOTES
REFERENCES

Trends in Gastric Cancer Incidence According to the Clinicopathological Characteristics in Korea, 1999-2014

Fig. 1. Incidence rates (per 100,000) of gastric cancer by age groups.

Fig. 1.

Trends in Gastric Cancer Incidence According to the Clinicopathological Characteristics in Korea, 1999-2014

Year	Overall		Cardia/Fundus		Body		Antrum/Pylorus		Non-specific
Year	No.	ASR^a)	No. (%)^b)	ASR^a)	No. (%)^b)	ASR^a)	No. (%)^b)	ASR^a)	No.	ASR^b)
1999	20,870	43.6	775 (6.8)	1.6	4,030 (35.3)	8.3	6,623 (58.0)	14.0	9,442	19.7
2000	20,972	42.3	813 (7.1)	1.7	4,067 (35.5)	8.1	6,591 (57.5)	13.4	9,501	19.1
2001	22,541	44.0	878 (6.6)	1.7	4,929 (37.3)	9.5	7,405 (56.0)	14.6	9,329	18.1
2002	23,220	43.6	999 (7.0)	1.9	5,223 (36.4)	9.7	8,123 (56.6)	15.4	8,875	16.6
2003	23,927	43.3	1,016 (6.8)	1.8	5,548 (37.0)	10.0	8,434 (56.2)	15.4	8,929	16.1
2004	23,636	41.2	1,013 (6.7)	1.8	5,737 (38.1)	10.0	8,304 (55.2)	14.6	8,582	14.9
2005	26,367	44.4	1,114 (6.3)	1.9	6,816 (38.4)	11.5	9,806 (55.3)	16.6	8,631	14.4
2006	26,434	42.9	1,208 (6.4)	2.0	7,173 (38.2)	11.6	10,386 (55.3)	17.0	7,667	12.3
2007	26,820	41.8	1,251 (6.3)	2.0	7,739 (39.1)	12.1	10,799 (54.6)	16.9	7,031	10.8
2008	28,394	42.6	1,326 (6.1)	2.0	8,664 (39.8)	13.1	11,758 (54.1)	17.8	6,646	9.8
2009	30,019	43.4	1,382 (5.9)	2.0	9,345 (39.8)	13.7	12,754 (54.3)	18.5	6,538	9.3
2010	30,680	42.6	1,495 (6.2)	2.1	9,534 (39.6)	13.4	13,056 (54.2)	18.2	6,595	9.0
2011	31,937	42.9	1,668 (6.3)	2.2	10,938 (41.5)	14.9	13,759 (52.2)	18.5	5,572	7.3
2012	31,067	40.2	1,662 (6.4)	2.1	10,993 (42.1)	14.5	13,442 (51.5)	17.3	4,970	6.2
2013	30,328	37.6	1,582 (6.2)	2.0	10,672 (42.0)	13.6	13,181 (51.8)	16.2	4,893	5.8
2014	29,854	35.8	1,566 (6.2)	1.9	10,981 (43.2)	13.6	12,849 (50.6)	15.2	4,458	5.1
APC (95% CI)	–0.9 (–1.4 to –0.3)		1.3 (0.6 to 2.1)		3.7 (2.9 to 4.6)		1.3 (0.3 to 2.2)		–8.5 (–9.3 to –7.7)
p-value	< 0.001		< 0.001		< 0.001		< 0.001		< 0.001

Age (yr)	Overall			Cardia/Fundus			Body			Antrum/Pylorus
Age (yr)	2004	2014	p-value	2004	2014	p-value	2004	2014	p-value	2004	2014	p-value
30-39	0.9 (0.8-1.0)	0.8 (0.7-0.9)	0.118	1.4 (0.8-2.4)	1.5 (0.8-2.8)	0.862	0.8 (0.7-1.0)	0.5 (0.5-0.6)	0.003	1.3 (1.1-1.6)	1.4 (1.1-1.9)	0.658
40-49	1.8 (1.6-1.9)	1.5 (1.4-1.6)	< 0.001	1.7 (1.2-2.4)	2.1 (1.5-3.0)	0.367	1.3 (1.1-1.5)	1.0 (0.9-1.1)	0.006	2.6 (2.3-3.0)	2.2 (2.0-2.5)	0.087
50-59	2.8 (2.6-3.0)	2.7 (2.6-2.9)	0.413	3.2 (2.3-4.3)	2.9 (2.3-3.8)	0.739	2.2 (1.9-2.4)	2.1 (1.9-2.2)	0.545	3.3 (2.9-3.6)	3.5 (3.2-3.8)	0.326
60-69	3.1 (2.9-3.2)	3.2 (3.1-3.4)	0.225	4.5 (3.6-5.8)	4.0 (4.0-6.2)	0.638	3.4 (3.1-3.8)	2.9 (2.7-3.1)	0.011	2.8 (2.6-3.0)	3.2 (3.0-3.5)	0.017
70-79	2.7 (2.5-2.8)	2.7 (2.6-2.8)	0.986	3.8 (2.9-5.0)	3.9 (3.2-4.7)	0.878	3.0 (2.7-3.4)	3.0 (2.8-3.3)	0.913	2.5 (2.3-2.8)	2.3 (2.2-2.5)	0.206
≥ 80	2.6 (2.4-2.9)	2.5 (2.3-2.7)	0.454	3.7 (2.3-6.1)	3.5 (2.6-4.6)	0.830	3.7 (2.9-4.8)	2.8 (2.5-3.3)	0.097	2.8 (2.3-3.3)	2.4 (2.2-2.7)	0.230

Tumor location	SEER	2006	2014	p-value
Overall	Localized	11,712 (53.9)	18,572 (66.0)	< 0.001
	Regional	6,819 (31.4)	6,335 (22.5)
	Distant	3,213 (14.8)	3,242 (11.5)
	Unknown	4,690	1,705
Cardia/Fundus	Localized	466 (44.4)	799 (54.2)	< 0.001
	Regional	392 (37.3)	453 (30.8)
	Distant	192 (18.3)	221 (15.0)
	Unknown	158	93
Body	Localized	3,497 (55.6)	6,999 (66.1)	< 0.001
	Regional	1,952 (31.0)	2,447 (23.1)
	Distant	841 (13.4)	1,136 (10.7)
	Unknown	883	399
Antrum/Pylorus	Localized	5,308 (59.3)	8,728 (70.8)	< 0.001
	Regional	2,671 (28.8)	2,589 (21.0)
	Distant	972 (10.9)	1,010 (8.2)
	Unknown	1,435	522

Age group (yr)	SEER	2006	2014	p-value
30-39	Localized	508 (45.3)	453 (55.5)	< 0.001
	Regional	375 (33.4)	198 (24.3)
	Distant	239 (21.3)	165 (20.2)
	Unknown	128	21
≥ 40	Localized	11,130 (54.4)	18,076 (66.4)	< 0.001
	Regional	6,396 (31.3)	6,118 (22.5)
	Distant	2,931 (14.3)	3,048 (11.2)
	Unknown	4,533	1,680

Year	Tubular adenocarcinoma	Signet ring cell	Other carcinoma	Carcinoid tumor	Non-epithelial tumor	Unclassified
1999	13,153 (75.9)^a)	3,348 (19.3)	653 (3.8)	50 (0.3)	133 (0.8)	3,533
2000	13,553 (75.8)	3,443 (19.3)	672 (3.8)	49 (0.3)	156 (0.9)	3,099
2001	14,964 (75.6)	3,918 (19.8)	660 (3.3)	45 (0.2)	199 (1.0)	2,755
2002	15,566 (75.4)	4,107 (19.9)	697 (3.4)	71 (0.3)	203 (1.0)	2,576
2003	16,334 (75.4)	4,235 (19.6)	778 (3.6)	79 (0.4)	227 (1.0)	2,274
2004	16,010 (74.2)	4,521 (20.9)	710 (3.3)	110 (0.5)	236 (1.1)	2,049
2005	18,357 (75.5)	4,755 (19.6)	832 (3.4)	128 (0.5)	232 (1.0)	2,063
2006	18,894 (76.1)	4,756 (19.2)	782 (3.2)	124 (0.5)	258 (1.0)	1,620
2007	18,973 (75.3)	5,006 (19.9)	828 (3.3)	133 (0.5)	260 (1.0)	1,620
2008	20,506 (75.6)	5,353 (19.7)	856 (3.2)	141 (0.5)	252 (0.9)	1,286
2009	21,877 (75.8)	5,576 (19.3)	951 (3.3)	174 (0.6)	282 (1.0)	1,159
2010	22,526 (76.4)	5,577 (18.9)	867 (2.9)	217 (0.7)	310 (1.1)	1,183
2011	23,488 (76.2)	5,870 (19.1)	865 (2.8)	255 (0.8)	328 (1.1)	1,131
2012	22,916 (76.2)	5,631 (18.7)	895 (3.0)	278 (0.9)	341 (1.1)	1,006
2013	21,982 (74.9)	5,849 (19.9)	918 (3.1)	260 (0.9)	356 (1.2)	963
2014	21,430 (74.0)	5,947 (20.5)	902 (3.1)	277 (1.0)	395 (1.4)	903
APC (95% CI)	3.8 (3.0-4.6)	3.8 (3.2-4.4)	2.4 (1.8-3.0)	13.0 (11.1-14.9)	5.9 (5.1-6.7)
p-value	< 0.001	< 0.001	< 0.001	< 0.001	< 0.001

Table 1. Age-standardized gastric cancer incidence rates per 100,000 and APCs by tumor location

APC, annual percent changes; ASR, age-standardized rate; CI, confidence interval.

The Segi’s world population was used as standard population,

Proportions of each tumor location excluding non-specific.

Table 2. Male to female gastric cancer incidence rate ratio by tumor location

Table 3. SEER stage distribution according to tumor location between 2006 and 2014

Values are presented as number (%). SEER, Surveillance Epidemiology and End Results.

Table 4. SEER stage distribution in 30s and 40s or more between 2006 and 2014

SEER, Surveillance Epidemiology and End Results.

Table 5. Incidences according to the histological classification

Values are presented as number (%). APC, annual percent changes; CI, confidence interval.